NCT02340104View on ClinicalTrials.gov

A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Healthy Volunteers
Interventions
DRUG

Baricitinib

4 milligrams (mg) administered orally

DRUG

[^13C4D3^15N]-baricitinib

4 micrograms (μg) administered intravenously (IV)

Trial Locations (1)

LS2 9LH

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY, Leeds

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02340104 - A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants | Biotech Hunter | Biotech Hunter